Do we really need five TNF antagonists? Or more insight into the use of existing options?

Eric M. Ruderman

doi:10.1093/rheumatology/keq016

Do we really need five TNF antagonists? Or more insight into the use of existing options?

Eric M. Ruderman^*

^*Corresponding author for this work

Medicine, Rheumatology Division

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Original language	English (US)
Article number	keq016
Pages (from-to)	1028-1029
Number of pages	2
Journal	Rheumatology
Volume	49
Issue number	6
DOIs	https://doi.org/10.1093/rheumatology/keq016
State	Published - Feb 19 2010

ASJC Scopus subject areas

Rheumatology
Pharmacology (medical)

Access to Document

10.1093/rheumatology/keq016

Cite this

@article{7a760f7a0642476183ea64abf2f36596,

title = "Do we really need five TNF antagonists? Or more insight into the use of existing options?",

author = "Ruderman, {Eric M.}",

note = "Funding Information: Disclosure statement: E.M.R. has received consulting fees from Abbott Immunology, Amgen/Wyeth and UCB. He has received research funding from Abbott Immunology and Centocor.",

year = "2010",

month = feb,

day = "19",

doi = "10.1093/rheumatology/keq016",

language = "English (US)",

volume = "49",

pages = "1028--1029",

journal = "Rheumatology and Rehabilitation",

issn = "1462-0324",